These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The role of pharmacologic modulation of autophagy on anal cancer development in an HPV mouse model of carcinogenesis. Rademacher BL; Matkowskyj KA; Meske LM; Romero A; Sleiman H; Carchman EH Virology; 2017 Jul; 507():82-88. PubMed ID: 28431282 [TBL] [Abstract][Full Text] [Related]
5. Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors. Gunder LC; Moyer TH; Johnson HR; Auyeung AS; Leverson GE; Zhang W; Matkowskyj KA; Carchman EH J Surg Res; 2023 Feb; 282():137-146. PubMed ID: 36274448 [TBL] [Abstract][Full Text] [Related]
6. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model. Matsushima M; Kikuchi E; Matsumoto K; Hattori S; Takeda T; Kosaka T; Miyajima A; Oya M Int J Oncol; 2015 Jul; 47(1):377-83. PubMed ID: 25963317 [TBL] [Abstract][Full Text] [Related]
7. Topical Protease Inhibitor Decreases Anal Carcinogenesis in a Transgenic Mouse Model of HPV Anal Disease. Gunder LC; Johnson HR; Yao E; Moyer TH; Green HA; Sherer N; Zhang W; Carchman EH Viruses; 2023 Apr; 15(4):. PubMed ID: 37112993 [TBL] [Abstract][Full Text] [Related]
8. Systemic Delivery of a Dual PI3K/mTOR Inhibitor More Effective than Topical Delivery in Preventing Anal Carcinogenesis in an HPV Transgenic Mouse Model. Gunder LC; Moyer TH; Ziolkowski MR; Keating MK; Leverson GE; Zhang W; Carchman EH J Cancer Sci Clin Ther; 2022; 6(2):157-173. PubMed ID: 36683775 [TBL] [Abstract][Full Text] [Related]
9. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer. Chen L; Jin T; Zhu K; Piao Y; Quan T; Quan C; Lin Z Oncotarget; 2017 Feb; 8(7):11937-11949. PubMed ID: 28060760 [TBL] [Abstract][Full Text] [Related]
10. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698 [TBL] [Abstract][Full Text] [Related]
11. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. Xia A; Li H; Li R; Lu L; Wu X Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933 [TBL] [Abstract][Full Text] [Related]
13. Effects of NVP-BEZ235 on the proliferation, migration, apoptosis and autophagy in HT-29 human colorectal adenocarcinoma cells. Yu Y; Yu X; Ma J; Tong Y; Yao J Int J Oncol; 2016 Jul; 49(1):285-93. PubMed ID: 27176231 [TBL] [Abstract][Full Text] [Related]
14. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway. Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209 [TBL] [Abstract][Full Text] [Related]
15. Activating Mutations in Shin MK; Payne S; Bilger A; Matkowskyj KA; Carchman E; Meyer DS; Bentires-Alj M; Deming DA; Lambert PF Clin Cancer Res; 2019 Mar; 25(6):1889-1900. PubMed ID: 30530704 [TBL] [Abstract][Full Text] [Related]
16. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683 [TBL] [Abstract][Full Text] [Related]
17. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma. Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells. Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150 [TBL] [Abstract][Full Text] [Related]
20. A Novel Model for Papillomavirus-Mediated Anal Disease and Cancer Using the Mouse Papillomavirus. Blaine-Sauer S; Shin MK; Matkowskyj KA; Ward-Shaw E; Lambert PF mBio; 2021 Aug; 12(4):e0161121. PubMed ID: 34281391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]